GemCap Biotech ApS: Financial statements 2023
CVR: 38189174
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
GemCap Biotech ApS (CVR 38189174) has filed annual accounts for 2023. In 2023, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2023 report amounted to EUR 27,000. The solvency ratio was 100%.
- Profit/Loss
- EUR 0
- Equity
- EUR 27,000
- Total Assets
- EUR 27,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | 0 EUR | 27 t. EUR | 0 |
| 2022 | - | - | 0 EUR | 27 t. EUR | - |
| 2021 | - | - | 0 EUR | 7 t. EUR | - |
| 2020 | - | - | 0 EUR | 7 t. EUR | - |
| 2019 | - | - | 0 EUR | 7 t. EUR | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
GemCap Biotech ApS has published its annual report for 2022. The net result was DKK 0.
About GemCap Biotech ApS
GemCap Biotech ApS was a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company has been dissolved on 24 March 2024. The company was registered under the industry Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n.. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2023 report amounted to EUR 27,000.